LONDON - When the going gets tough, the tough get going. "That title was fixed some weeks ago, but it turns out to be more relevant than I ever imagined," said the keynote speaker David Brennan, CEO of AstraZeneca plc, addressing BioPartnering Europe delegates Monday. (BioWorld International) Read More
No Abstract BioWorld International CorrespondentPARIS - Endotis Pharma, which is developing small-glyco drugs for applications in thrombosis and oncology, has obtained public funding of €4.5 million (US6.1 million) from three sources to finance ongoing research programs. Read More
